Synthesis of a thymosin beta 4-like peptide, deacetyl-thymosin beta Xen4, and its restorative effect on depressed lymphocyte blastogenic response to phytohemagglutinin (PHA) in uremic patients.
Abiko. T T; Sekino. H H
Key Findings
- A deacetyl‑thymosin beta Xen4 peptide was chemically synthesized from six fragments.
- The synthetic peptide restored the weakened blastogenic response of T‑lymphocytes from uremic patients to phytohemagglutinin (PHA).
- The study indicates that thymosin‑beta‑4‑like fragments can have immunomodulatory effects in vitro.
Practical Outcomes
- The finding hints that this peptide might improve immune function in people with kidney disease, but it remains an early laboratory observation. No dosage, safety data, or human efficacy studies are available, so it is not ready for self‑experimentation or inclusion in longevity protocols.
Summary
Scientists created a frog‑derived peptide similar to thymosin beta‑4 and showed that, in a lab test, it helped immune cells from kidney‑failure patients respond better to a stimulus. The work is purely experimental and does not provide a usable protocol for everyday supplementation.
Abstract
An analog of thymosin beta Xen4 isolated from oocytes of Xenopus laevis, deacetyl-thymosin beta Xen4, was synthesized by assembling 6 peptide fragments, followed by deprotection with 1 M trifluoromethanesulfonic acid-thioanisole (molar ratio, 1:1) in trifluoroacetic acid in the presence of dimethylselenium. Finally, the deprotected peptide was incubated with dithiothreitol to reduce sulfoxide on the methionine side chain. The synthetic tritetracontapeptide was found to have a restoring effect on the impaired blastogenic response of T-lymphocytes isolated from uremic patients.
Study Information
pubmed
1989
10.1248/cpb.37.2467